ArticleCancer research2019
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 46 citations in OpenAlex.
- MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.Oncogene · 2026Article
- Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.Journal of neuropathology and experimental neurology · 2026Article
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.Cancer research · 2026Review
- MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies.Cells · 2025Review
- Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.International journal of molecular sciences · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- The glioma microenvironment and its impact on antitumor immunity.Neuro-oncology advances · 2025Review
- PAICS-Driven Purine Biosynthesis and Its Prognostic Implications in Lung Adenocarcinoma: A Novel Risk Stratification Model and Therapeutic Insights.Current issues in molecular biology · 2025Article
- Resilience and vulnerabilities of tumor cells under purine shortage stress.bioRxiv : the preprint server for biology · 2025Article
- Targeting RNA splicing modulation: new perspectives for anticancer strategy?Journal of experimental & clinical cancer research : CR · 2025Review
- MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.Nature communications · 2025Article
- Integrative analysis of polyamine metabolism-related genes in gliomas: implications for prognosis and therapy.Frontiers in oncology · 2025Article
- Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.The oncologist · 2024Article
- Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake ofJournal of neuro-oncology · 2024Article
- Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.Journal of neuropathology and experimental neurology · 2024Article
- Prognostic Value of Immunohistochemical Expression of MTAP and AKIP1 in IDH1 Mutant Astrocytoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Article
- Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The potential and challenges of targetingFrontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 2 countries.
Landon J Hansen *The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-7492-3997
Ran Sun *The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2934-3731
Rui YangThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Simranjit X SinghThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2556-9696
Lee H ChenThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Christopher J PirozziThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Casey J MoureThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Carlee HemphillThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Austin B CarpenterThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Patrick HealyDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Ryan C RugerThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Chin-Pu J ChenThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Paula K GreerThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Fangping ZhaoGenetron Health Technologies, Inc., Research Triangle Park, North Carolina.
Ivan SpasojevicDepartment of Medicine, Duke University Medical Center, Durham, North Carolina.
Carole GrenierDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Zhiqing HuangDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Susan K MurphyDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Roger E McLendonThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-6682-4588
Henry S FriedmanThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7588-032X
Allan H FriedmanThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7588-032X
James E HerndonDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
John H SampsonThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Stephen T KeirThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Darell D BignerThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Hai YanThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Yiping HeThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina. yiping.he@dm.duke.edu.
Duke University · USDuke Medical Center · USPediatric Brain Tumor Foundation · USBD Technologie (United States) · USUnion Hospital · CN
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTargeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MOncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of GliomasR35CA197264 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 2015 to 2021
$6.1MExploiting MTAP deletion for GBM therapeuticsR01NS101074 · NINDS · DUKE UNIVERSITY · PI HE, YIPING · 2017 to 2021
$1.7MExploring the therapeutic potential and pathogenic contribution of MTAP deletion in GlioblastomaF30CA206336 · NCI · DUKE UNIVERSITY · PI HANSEN, LANDON JOHN · 2017 to 2018
$85kNCI NIH HHS F30 CA206336NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA190991NCI NIH HHS R35 CA197264NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449NINDS NIH HHS R01 NS101074
Abstract
Homozygous deletion of methylthioadenosine phosphorylase (
Indexed as
Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell ProliferationGlioblastomaHumansMiceNeoplastic Stem CellsPrognosisPurine-Nucleoside PhosphorylasePurinesSurvival RateTumor Cells, CulturedXenograft Model Antitumor Assays5'-methylthioadenosine phosphorylaseBiomarkers, TumorPurine-Nucleoside PhosphorylasePurines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.